Sino Biopharmaceutical Limited
1177
Rank in Stocks
#1753
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Share Price
$0.69080164
Market Cap
$12.30B
Change (1 day)
2.86%
Change (1 year)
-27.78%
Country
HK
Trade Sino Biopharmaceutical Limited (1177)
Category
Healthcare
P/E ratio for Sino Biopharmaceutical Limited (1177)
P/E ratio as of October 2026 TTM: 33.58
According to Sino Biopharmaceutical Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 33.58. At the end of 2023 the company had a P/E ratio of 30.45.
P/E ratio history for Sino Biopharmaceutical Limited from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 33.58 | 125.39% |
| 2024 | 14.90 | -51.06% |
| 2023 | 30.45 | 3.06% |
| 2022 | 29.54 | 417.13% |
| 2021 | 5.71 | -86.65% |
| 2020 | 42.81 | 64.50% |
| 2019 | 26.02 | 320.41% |
| 2018 | 6.19 | -84.21% |
| 2017 | 39.19 | 85.12% |
| 2016 | 21.17 | -28.05% |
| 2015 | 29.42 | 27.86% |
| 2014 | 23.01 | -21.27% |
| 2013 | 29.23 | 42.22% |
| 2012 | 20.55 | -16.96% |
| 2011 | 24.75 | 0.93% |
| 2010 | 24.52 | -12.56% |
| 2009 | 28.05 | 251.36% |
| 2008 | 7.98 | -46.51% |
| 2007 | 14.92 | -0.88% |
| 2006 | 15.06 | 609.85% |
| 2005 | 2.12 | -82.99% |
| 2004 | 12.47 | -8.04% |
| 2003 | 13.56 | 192.22% |
| 2002 | 4.64 | 9.00% |
| 2001 | 4.26 | -13.69% |
| 2000 | 4.93 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 24.47 | -27.13% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 223.52 | 565.57% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.